Shorts
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)
Clinical relationship between the heart and the kidneys
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)
Why is empagliflozin now a preferred heart failure treatment, coming from a history of diabetes?
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)
How has recent evidence and the ESC 2023 guidelines changed management of heart failure?
Theresa McDonagh (United Kingdom)
What's new for the treatment of chronic heart failure from the ESC 2023 guidelines?
Subodh Verma (Canada)
Why should empagliflozin be your first choice in heart failure management?
Lee-Ling Lim (Malaysia)
Why is organ protection crucial in patients with cardiorenal metabolic conditions?
Lee-Ling Lim (Malaysia)
Reducing the risk of diabetic ketoacidosis when initiating SGLT2 inhibitors
Lee-Ling Lim (Malaysia)
Expert opinion on reducing the risk of genital infections and UTIs when initiating SGLT2 inhibitors
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)
The heart failure patient through a holistic lens (Summary)
Practical tips on initiating SGLT2 inhibitors in elderly/frail patients
Subodh Verma (Canada)
Benefits of starting an SGLT2 inhibitor upon clinical diagnosis of heart failure
Subodh Verma (Canada)
Crucial patients for high index suspicion of heart failure
Paweena Susantitaphong (Thailand)
Expert opinion on the eGFR dip when initiating SGLT2 inhibitors
Subodh Verma (Canada) | Soo Yong Lee (Korea)
SGLT2 inhibitor: Essential foundation for heart failure treatment (Summary 1)
Subodh Verma (Canada) | Soo Yong Lee (Korea)
SGLT2 inhibitor: Essential foundation for heart failure treatment (Summary 2)
Andrew Coats (Australia)
Heart failure treatment from then to now (Summary 2)
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)
Is the initial eGFR dip a cause for concern?
Andrew Coats (Australia)
What is the impact of SGLT2 inhibitor trials in HFpEF?
Andrew Coats (Australia)